{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:11:13Z","timestamp":1755216673956,"version":"3.43.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>No-reflow following primary percutaneous coronary intervention (PPCI) is challenging to treat.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objectives<\/jats:title>\n            <jats:p>The objective of this study is to evaluate the efficacy and safety of upstream high-bolus-dose tirofiban administration in ST-segment elevation myocardial infarction (STEMI) cases undergoing PPCI on top of dual antiplatelet therapy, including ticagrelor, in comparison to selective bailout administration.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This hospital-based, randomized, single-blinded prospective interventional study was conducted on 150 patients at Assiut University Heart Hospital. Patients with STEMI within 12\u2005h after symptom onset who underwent PPCI were randomized to an upstream group (<jats:italic toggle=\"yes\">n<\/jats:italic>\u2005=\u200575) and a selective bailout group (<jats:italic toggle=\"yes\">n<\/jats:italic>\u2005=\u200575) based on the timing of the tirofiban bolus administration (25\u2005\u00b5g\/kg intravenously over 5\u2005min).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The bailout group\u2019s thrombolysis in myocardial infarction (TIMI) frame count was higher than the upstream group\u2019s, despite comparable TIMI flow and myocardial blush grade between the two groups, but only approached statistical significance [14.4 (4\u201336) vs 12.2 (5\u201355), <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u20050.08]. The enzymatic infarct size tended to be lower in the upstream group. All echocardiographic findings were comparable between the two studied groups, with no significant difference (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&gt;\u20050.05). There was no significant difference between the two groups regarding clinical outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Compared to selective bailout administration, upstream high bolus dose of tirofiban in STEMI patients undergoing primary coronary intervention did not significantly affect angiographic outcomes, left ventricular remodeling, or function, despite smaller infarction size.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mca.0000000000001501","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T07:00:23Z","timestamp":1737529223000},"page":"488-495","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Short-term effects of upstream high bolus dose of tirofiban in patients with ST segment elevation myocardial infarction undergoing primary percutaneous coronary intervention"],"prefix":"10.1097","volume":"36","author":[{"given":"Amr E.I.","family":"Abouelnour","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Assiut University Heart Hospital, Assiut, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eman Q.","family":"Mohammed","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Assiut University Heart Hospital, Assiut, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doaa A.","family":"Fouad","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Assiut University Heart Hospital, Assiut, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aly","family":"Tohamy","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Assiut University Heart Hospital, Assiut, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"R1-20250804","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1161\/CIRCINTERVENTIONS.111.962787","article-title":"Primary percutaneous coronary intervention as a national reperfusion strategy in patients with ST-segment elevation myocardial infarction.","volume":"4","author":"Terkelsen","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"key":"R2-20250804","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1093\/eurheartj\/ehq299","article-title":"No-reflow: again prevention is better than treatment.","volume":"31","author":"Niccoli","year":"2010","journal-title":"Eur Heart J"},{"key":"R3-20250804","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.3390\/jcm11082233","article-title":"\u2018No-reflow\u2019 phenomenon: a contemporary review.","volume":"11","author":"Annibali","year":"2022","journal-title":"J Clin Med"},{"key":"R4-20250804","doi-asserted-by":"crossref","first-page":"85","DOI":"10.4103\/1995-705X.102145","article-title":"High bolus tirofiban vs abciximab in acute STEMI patients undergoing primary PCI-The Tamip study.","volume":"13","author":"Balghith","year":"2012","journal-title":"Heart Views"},{"key":"R5-20250804","doi-asserted-by":"crossref","first-page":"899","DOI":"10.5152\/akd.2014.5656","article-title":"The effects of tirofiban infusion on clinical and angiographic outcomes of patients with STEMI undergoing primary PCI.","volume":"15","author":"Kaymaz","year":"2015","journal-title":"Anatol J Cardiol"},{"key":"R6-20250804","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC).","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"key":"R7-20250804","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ehj.2014.05.003","article-title":"Impact of upstream high bolus dose tirofiban on left ventricular systolic function in patients with acute anterior myocardial infarction treated by primary coronary intervention.","volume":"66","author":"Galal","year":"2014","journal-title":"Egypt Heart J"},{"key":"R8-20250804","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0735-1097(00)00804-4","article-title":"Myocardial infarction redefined\u2014a consensus document of the Joint European Society of Cardiology\/American College of Cardiology committee for the redefinition of myocardial infarction: the Joint European Society of Cardiology\/American College of Cardiology Committee.","volume":"36","author":"Antman","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"R9-20250804","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3758\/BF03193146","article-title":"G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences.","volume":"39","author":"Faul","year":"2007","journal-title":"Behavior Research Methods"},{"key":"R10-20250804","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ajem.2010.10.011","article-title":"Killip classification in patients with acute coronary syndrome: insight from a multicenter registry.","volume":"30","author":"El-Menyar","year":"2012","journal-title":"Am J Emerg Med"},{"key":"R11-20250804","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1161\/01.CIR.97.23.2302","article-title":"Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade.","volume":"97","author":"van \u2018t Hof","year":"1998","journal-title":"Circulation"},{"key":"R12-20250804","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1016\/j.jacc.2004.07.014","article-title":"ACC\/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction).","volume":"44","author":"Antman","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"R13-20250804","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1161\/01.CIR.103.21.2550","article-title":"Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy.","volume":"103","author":"Gibson","year":"2001","journal-title":"Circulation"},{"key":"R14-20250804","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1161\/01.CIR.76.1.142","article-title":"Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.","volume":"76","author":"Chesebro","year":"1987","journal-title":"Circulation"},{"key":"R15-20250804","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1161\/01.CIR.99.15.1945","article-title":"Relationship between TIMI frame count and clinical outcomes after thrombolytic administration.","volume":"99","author":"Gibson","year":"1999","journal-title":"Circulation"},{"key":"R16-20250804","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0140-6736(08)61235-0","article-title":"Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial.","volume":"372","author":"Van\u2019t Hof","year":"2008","journal-title":"Lancet"},{"key":"R17-20250804","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium.","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"R18-20250804","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions.","volume":"115","author":"Cutlip","year":"2007","journal-title":"Circulation"},{"key":"R20-20250804","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1161\/CIRCULATIONAHA.107.747642","article-title":"Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial.","volume":"118","author":"Thiele","year":"2008","journal-title":"Circulation"},{"key":"R21-20250804","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1161\/CIRCULATIONAHA.109.882746","article-title":"Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb\/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial.","volume":"121","author":"Deibele","year":"2010","journal-title":"Circulation"},{"key":"R22-20250804","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes.","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"R23-20250804","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1093\/eurheartj\/ehn416","article-title":"Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology.","volume":"29","author":"Van de Werf","year":"2008","journal-title":"Eur Heart J"},{"key":"R24-20250804","doi-asserted-by":"crossref","first-page":"065","DOI":"10.1055\/s-0039-1700546","article-title":"Efficacy and safety of glycoprotein IIb\/IIIa inhibitors on top of ticagrelor in STEMI: a subanalysis of the ATLANTIC trial.","volume":"120","author":"Tavenier","year":"2020","journal-title":"Thromb Haemost"},{"key":"R25-20250804","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ahj.2004.07.015","article-title":"ST resolution in a single electrocardiographic lead: a simple and accurate predictor of cardiac mortality in patients with fibrinolytic therapy for acute ST-elevation myocardial infarction.","volume":"149","author":"Zeymer","year":"2005","journal-title":"Am Heart J"},{"key":"R26-20250804","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/BF01907131","article-title":"Determinants of infarct size in non-human primates.","volume":"85","author":"Flameng","year":"1990","journal-title":"Basic Res Cardiol"},{"key":"R27-20250804","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/clc.20551","article-title":"Upstream high\u2010dose tirofiban does not reduce myocardial infarct size in patients undergoing primary percutaneous coronary intervention: a magnetic resonance imaging pilot study.","volume":"32","author":"Song","year":"2009","journal-title":"Clin Cardiol"},{"key":"R28-20250804","first-page":"E204","article-title":"Glycoprotein IIb\/IIIa inhibitor use in patients with acute myocardial infarction undergoing PCI: insights from the TRANSLATE ACS study.","volume":"93","author":"Ibrahim","year":"2019","journal-title":"Catheter Cardiovasc Interv"},{"key":"R29-20250804","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.2147\/DDDT.S138714","article-title":"Efficacy and safety of quadruple therapy including tirofiban in the treatment of Chinese NSTE-ACS patients failing to receive timely percutaneous coronary intervention.","volume":"21","author":"Li","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"R30-20250804","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jcin.2008.05.007","article-title":"Trends in the prevalence and outcomes of radial and femoral approaches to percutaneous coronary intervention: a report from the National Cardiovascular Data Registry.","volume":"1","author":"Rao","year":"2008","journal-title":"JACC Cardiovasc Interv"},{"key":"R31-20250804","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0140-6736(98)11086-3","article-title":"Platelet GPIIb\u2013IIIa blockers.","volume":"353","author":"Topol","year":"1999","journal-title":"Lancet"}],"container-title":["Coronary Artery Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000001501","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T16:00:48Z","timestamp":1754323248000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000001501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/mca.0000000000001501","relation":{},"ISSN":["0954-6928","1473-5830"],"issn-type":[{"type":"print","value":"0954-6928"},{"type":"electronic","value":"1473-5830"}],"subject":[],"published":{"date-parts":[[2025,7,30]]}}}